Xequte User Forums
Xequte User Forums
Profile | Join | Active Topics | Search | Forum FAQ
     
Forum Tips
» This forum is for users to discuss their software problems and suggestions for improvement.  Remember that only a tiny percentage of our users experience such problems (To be precise less than 0.7% have ever posted on this forum)
» Include your software version number (as displayed in the About Box)
» Check the FAQ before posting as most common questions have already been answered
» You don't need to also e-mail us separately as our support team will respond to all questions on this forum
 
 All Forums
 Xequte User Forums
 MailList King
 trop 2 adc

Note: You must be registered in order to post a reply.
To register, click here. Registration is FREE!

Screensize:
UserName:
Password:
Format Mode:
Format: BoldItalicizedUnderlineStrikethrough Align LeftCenteredAlign Right Horizontal Rule Insert HyperlinkInsert EmailInsert Image Insert CodeInsert QuoteInsert List
   
Message:

* HTML is OFF
* Forum Code is ON
Smilies
Smile [:)] Big Smile [:D] Cool [8D] Blush [:I]
Tongue [:P] Evil [):] Wink [;)] Clown [:o)]
Black Eye [B)] Eight Ball [8] Frown [:(] Shy [8)]
Shocked [:0] Angry [:(!] Dead [xx(] Sleepy [|)]
Kisses [:X] Approve [^] Disapprove [V] Question [?]

  Attach a photo to your post
 
Check here to subscribe to this topic.
   

T O P I C    R E V I E W
catalinagarcia Posted - Oct 17 2024 : 23:12:24
A growing body of evidence suggests that TROP2 is a promising molecular target for the treatment of various malignancies. As novel targeted therapy with great potential, antibody-drug conjugates (ADCs) targeting a specific antigen inherit superiorities of antibody with the drug module, and more remarkably, expand the therapeutic window. For more information about trop 2 adc: https://www.creative-biolabs.com/adc/adc-development-services-targeting-trop2.htm